

# Barry E Storer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7930544/publications.pdf>

Version: 2024-02-01

40  
papers

6,062  
citations

201385

27  
h-index

360668

35  
g-index

40  
all docs

40  
docs citations

40  
times ranked

6666  
citing authors

#	ARTICLE	IF	CITATIONS
1	Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, 18, 695-706.		2,407
2	Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood, 2003, 101, 1620-1629.	0.6	424
3	Comorbidity-Age Index: A Clinical Measure of Biologic Age Before Allogeneic Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2014, 32, 3249-3256.	0.8	361
4	Transplantation of Marrow Cells From Unrelated Donors for Treatment of High-Risk Acute Leukemia: The Effect of Leukemic Burden, Donor HLA-Matching, and Marrow Cell Dose. Blood, 1997, 89, 4226-4235.	0.6	358
5	Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood, 2004, 104, 3501-3506.	0.6	269
6	Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood, 2009, 114, 702-708.	0.6	218
7	Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2013, 31, 1530-1538.	0.8	197
8	Adjuvant Radiation Therapy and Chemotherapy in Merkel Cell Carcinoma: Survival Analyses of 6908 Cases From the National Cancer Data Base. Journal of the National Cancer Institute, 2016, 108, djw042.	3.0	170
9	Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood, 2007, 110, 2744-2748.	0.6	156
10	Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood, 2009, 113, 5074-5082.	0.6	143
11	Biomarker Panel for Chronic Graft-Versus-Host Disease. Journal of Clinical Oncology, 2016, 34, 2583-2590.	0.8	118
12	Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment. Blood, 2015, 126, 113-120.	0.6	110
13	Failure-free survival after initial systemic treatment of chronic graft-versus-host disease. Blood, 2014, 124, 1363-1371.	0.6	86
14	Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. Lancet Haematology, the, 2019, 6, e409-e418.	2.2	84
15	A Diagnostic for Cox Regression and General Conditional Likelihoods. Journal of the American Statistical Association, 1985, 80, 139-147.	1.8	81
16	Hematopoietic Stem-Cell Transplantation for Treatment-Related Leukemia or Myelodysplasia. Journal of Clinical Oncology, 2001, 19, 2134-2141.	0.8	79
17	Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study. Haematologica, 2012, 97, 451-458.	1.7	77
18	Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. Blood, 2011, 118, 456-463.	0.6	75

#	ARTICLE	IF	CITATIONS
19	Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. <i>Blood</i> , 2013, 121, 2340-2346.	0.6	55
20	An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease. <i>Blood</i> , 2017, 130, 360-367.	0.6	52
21	Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 386-392.	2.0	52
22	Treosulfan-Based Conditioning and Hematopoietic Cell Transplantation for Nonmalignant Diseases: A Prospective Multicenter Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1996-2003.	2.0	51
23	Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 555-562.	2.0	50
24	Clinical Benefit of Response in Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1517-1524.	2.0	47
25	Treosulfan, Fludarabine, and 2-Gy Total Body Irradiation Followed by Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 549-555.	2.0	47
26	Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors. <i>Blood</i> , 2016, 128, 2350-2358.	0.6	43
27	Low-Dose Total Body Irradiation and Fludarabine Conditioning for HLA Class I-Mismatched Donor Stem Cell Transplantation and Immunologic Recovery in Patients with Hematologic Malignancies: A Multicenter Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 384-394.	2.0	39
28	Predictive Value of Clinical Findings and Plasma Biomarkers after Fourteen Days of Prednisone Treatment for Acute Graft-versus-host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1257-1263.	2.0	29
29	Comparison of Short-Term Response and Long-Term Outcomes after Initial Systemic Treatment of Chronic Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 124-132.	2.0	26
30	A Diagnostic for Cox Regression and General Conditional Likelihoods. , 0, .		24
31	Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, 18, 695.		22
32	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Research Methodology and Study Design Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 10-23.	2.0	20
33	Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 956-963.	2.0	18
34	Disability Related to Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 772-777.	2.0	16
35	Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen mismatched donors. <i>Blood</i> , 2020, 136, 1499-1506.	0.6	16
36	Early Mixed Lymphoid Donor/Host Chimerism is Associated with Improved Transplant Outcome in Patients with Primary or Secondary Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2197-2203.	2.0	12

#	ARTICLE	IF	CITATIONS
37	Ixazomib for Treatment of Refractory Chronic Graft-versus-Host Disease: A Chronic GVHD Consortium Phase II Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1612-1619.	2.0	12
38	Carfilzomib for Treatment of Refractory Chronic Graft-versus-Host Disease: A Chronic GVHD Consortium Pilot Phase II Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 278-284.	2.0	10
39	Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, 18, 695.		8
40	Donor Lymphocyte Infusion for Relapsed Hematological Malignancies After Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial CD3+ T Cell Dose. <i>Blood</i> , 2012, 120, 354-354.	0.6	0